Department of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.
Center for Biomarker Research in Medicine (CBmed), 8010 Graz, Austria.
Nutrients. 2020 Jun 23;12(6):1874. doi: 10.3390/nu12061874.
Probiotics have been used in trials to therapeutically modulate the gut microbiome and have shown beneficial effects in cirrhosis. However, their effect on the microbiome of cirrhosis patients is not fully understood yet. Here, we tested the effects of a multispecies probiotic on microbiome composition in compensated cirrhosis. The gut microbiome composition of 58 patients with compensated cirrhosis from a randomized controlled trial who received a daily dose of multispecies probiotics or placebo for six months was analysed by 16S rRNA gene sequencing. Microbiome composition of patients who received probiotics was enriched with probiotic strains and the abundance of , , , and a species was increased in the probiotic group compared to the placebo group. Patients who had microbiome changes in response to probiotic treatment also showed a significant increase in neopterin and a significant decrease in faecal zonulin levels after intervention, which was not observed in placebo-treated patients or patients with unchanged microbiome compositions. In conclusion, multispecies probiotics may enrich the microbiome of compensated cirrhotic patients with probiotic bacteria during a six-month intervention and beneficially change the residential microbiome and gut barrier function.
益生菌已被用于临床试验中,以治疗性地调节肠道微生物组,并在肝硬化中显示出有益的效果。然而,它们对肝硬化患者微生物组的影响尚未完全了解。在这里,我们测试了一种多菌种益生菌对代偿期肝硬化患者微生物组组成的影响。通过 16S rRNA 基因测序,分析了来自一项随机对照试验的 58 名接受多菌种益生菌或安慰剂治疗 6 个月的代偿期肝硬化患者的肠道微生物组组成。接受益生菌治疗的患者的微生物组组成富含益生菌菌株,与安慰剂组相比,益生菌组中 、 、 、 和一种 物种的丰度增加。对益生菌治疗有微生物组变化的患者在干预后也显示出神经氨酸酶显著增加,粪便紧密素水平显著降低,而在接受安慰剂治疗的患者或微生物组组成未改变的患者中未观察到这种情况。总之,多菌种益生菌可能会在 6 个月的干预期间使代偿期肝硬化患者的微生物组富含益生菌细菌,并有益地改变居住微生物组和肠道屏障功能。